Acadia Pharmaceuticals Inc. (ACAD) reported second-quarter 2024 earnings of 20 cents per share, beating the Zacks Consensus Estimate of 16 cents. In the year-ago quarter, the company had recorded earnings of 1 cent per share.The bottom line improved year over year owing to higher product sales.Acadia recorded total revenues of $242 million, which beat the Zacks Consensus Estimate of$235 million. ACAD’s net product revenues comprise revenues generated from the sale of its two marketed products, Nuplazid (pi ...